TMCnet News
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
Breda, the Netherlands – October 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the Phase 3 ADAPT trial of efgartigimod for the treatment of generalized myasthenia gravis (gMG). The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021. "The additional ADAPT data presented during these important neuromuscular forums strengthen our understanding of the value efgartigimod can offer as a potential treatment for people living with gMG. Depth and consistency of disease score improvement, as well as a patient's ability to mount a vaccine response, are all key considerations for a treating physician," commented Wim Parys, M.D., Chief Medical Officer of argenx. "We are also presenting the first data from our real-world evidence study, through which we learn more about the severity of gMG and how it can impair a person's ability to function and negatively impact their quality of life. We will continue to listen to patients in uncovering the real-world burden associated with management of this debilitating, chronic disease." AANEM Presentations Title: “Examination of the Efficacy, Safety, And Tolerability of Efgartigimod in Acetylcholine Receptor Autoantibody Seronegative Patients with Generalized Myasthenia Gravis: Subgroup Analysis of the Phase 3 ADAPT Study” Winner, President Research Initiative Award Title: “Minimal Symptom Expression in Patients with Generalized Myasthenia Gravis from Treatment with Efgartigimod” Runner Up, Best Abstract Title: “Real-world Patient-reported Impact of Myasthenia Gravis: Initial Data From the MyRealWorld® MG Study” Title: “Patient Burden of Generalized Myasthenia Gravis” Session: Abstract Poster Session III and IV Title: “Generalized Myasthenia Gravis Management and Practice Guidelines: Cross-Sectional Survey of Community Neurologists in the United States.” Date and Time: Friday, October 15 from 1:00pm - 1:30pm MDT; 3:30pm - 4:00pm MDT Location: Poster Hall Title: “Diagnostic Adjudication of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) In the ADHERE Trial: Review of the First 100 Cases” In addition to the poster sessions listed above, argenx will host a sponsored industry forum at AANEM: Title: “Burden, Comorbidities, and Treatment in Generalized Myasthenia Gravis: Where Do We Stand?” MGFA Presentations Title: “Real-world Patient-reported Impact of Myasthenia Gravis: Initial Data From the MyRealWorld MG Study” Title: “Efgartigimod Treatment of Patients with Generalized Myasthenia Gravis Demonstrates Consistent Improvements Across All Muscle Subgroups and Regardless of Background Immunosuppressive Therapy” Title: “Effect of Efgartigimod, A Neonatal Fc Receptor Blocker, on Humoral Vaccine Responses in Autoimmune Patients” Posters Title: “Real World IVIG Usage in U.S. Adults With Generalized Myasthenia Gravis" About MG About CIDP About Efgartigimod About argenx Media: Joke Comijn Investors: Michelle Greenblatt Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should and include statements argenx makes concerning the clinical data of its product candidates; the intended results of its strategy; the momentum of its product candidate pipeline as well as argenx’s statements regarding research advancements and number of treatment options; and its plans to partner with advocacy organizations. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law. # # # Attachment |